Ivonescimab Anti- PD-1/ Anti-VEGF Molecule
Summit’s compound, ivonescimab, is an investigational therapy not approved by any regulatory authority other than China’s NMPA. Ivonescimab is a potential first-in-class bispecific antibody combining the effects of immunotherapy via anti-PD-1 with anti-angiogenesis effects of anti-VEGF in a single molecule. Ivonescimab displays cooperative binding to these targets with increased avidity in the tumor microenvironment. Summit’s Phase III NSCLC trials: HARMONi/NCT6396065, HARMONi-3/NCT05899608, HARMONi-7/NCT06767514.
...
More Info Less Info